NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

ImmuPharma PLC (IMM)

London
Currency in GBP
Disclaimer
2.28
+0.13(+6.05%)
Real-time Data
IMM Scorecard
Fair Value
Day's Range
2.172.28
52 wk Range
0.823.00
Bid/Ask
2.11 / 2.28
Prev. Close
2.15
Open
2.17
Day's Range
2.17-2.28
52 wk Range
0.82-3
Volume
149,656
Average Volume (3m)
1,562,957
1-Year Change
2.38%
Shares Outstanding
416,437,265
Fair Value
Unlock
Dividends Payment Streak
Unlock
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More

People Also Watch

1.60
GDRG
-10.00%
0.0875
BOIL
+6.06%
1.368
ARCMA
-5.66%
1.195
AYM
+8.64%
2.7400
VALX
+1.48%
How do you feel today about IMM?
Vote to see community's results!
or

ImmuPharma PLC Company Profile

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company’s lead product candidate is the P140 (Lupuzor), a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140 which is in Phase II for chronic inflammatory demyelinating polyneuropathy, a progressive inflammatory condition of the nerves; and P140 in other indications for asthma, gout, periodontitis, and IBD. Its pre-clinical products include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations for serious and life-threatening fungal infections, such as aspergillosis; and BioCin, a vancomycin based treatment for anti-infection treatment. It has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of 1P40 platform; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.